miRNAs: mediators of ErbB family targeted therapy resistance.

about

ErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases.

P2860

Q37668848-7A4F2DD8-4B7F-4F2D-AE08-9DC1E1FA50A6

P2860

miRNAs: mediators of ErbB family targeted therapy resistance.

Item

http://www.wikidata.org/entity/Q38881549

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

miRNAs: mediators of ErbB family targeted therapy resistance.

@en

type

Item

label

miRNAs: mediators of ErbB family targeted therapy resistance.

@en

prefLabel

miRNAs: mediators of ErbB family targeted therapy resistance.

@en

P1476

miRNAs: mediators of ErbB family targeted therapy resistance.

@en

P2093

Ana Luísa Teixeira

http://www.w3.org/2001/XMLSchema#string

Bárbara Filipa Adem

http://www.w3.org/2001/XMLSchema#string

Francisca Dias

http://www.w3.org/2001/XMLSchema#string

Nuno Ricardo Alves Bastos

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Cancer genome landscapes

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

P304

1175-1187

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS-2016-0038

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nuno Ricardo Alves Bastos

P577

2016-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27359187

http://www.w3.org/2001/XMLSchema#string

miRNAs: mediators of ErbB family targeted therapy resistance.

about

P2860

P2860

miRNAs: mediators of ErbB family targeted therapy resistance.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698